FibroGen Inc. is a biotechnology company engaged in the discovery, development, and commercialization of novel therapeutics. The primary focus of the company is on areas involving fibrosis, chronic kidney disease, anemia, and cancer, striving to address significant unmet medical needs. FibroGen's lead product candidate, roxadustat, is a hypoxia-inducible factor prolyl hydroxylase inhibitor intended for treating anemia related to chronic kidney disease in both dialysis and non-dialysis patients. Another pivotal pipeline offering includes pamrevlumab, which is being developed for serious fibrotic diseases and cancers. FibroGen operates in a highly specialized sector, significantly impacting healthcare and pharmaceutical industries by extending therapeutic options for conditions with few existing treatments. Based in San Francisco, California, FibroGen contributes to advancing medical research and expanding the possibilities within biomedicine, reinforcing its position as a key player in the quest for novel healthcare solutions.